-

ARQ SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Arq, Inc. (“Arq” or the “Company”) (NASDAQ:ARQ) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On March 9, 2026, that it decided to “pause GAC production to conduct a comprehensive engineering and production process optimization review of the path forward for the Company’s GAC business. As a result, the Company does not expect any GAC production in fiscal year 2026.” On this news, the price of Arq shares declined by $1.56 per share, or approximately 48.8%, from $3.20 per share on March 9, 2026 to close at $1.64 on March 10, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Arq securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:ARQ

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

MONTAUK RENEWABLES, INC. INVESTIGATION: MNTK Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Montauk Renewables, Inc. (“Montauk” or the “Company”) (NASDAQ: MNTK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Montauk securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.c...

GILAT SATELLITE NETWORKS LTD. INVESTIGATION: GILT Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Gilat Satellite Networks Ltd. (“Gilat” or the “Company”) (NASDAQ: GILT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Gilat securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp....

BRIGHT MINDS BIOSCIENCES DRUG INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 52.3% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Bright Minds Biosciences (“Bright Minds” or the “Company”) (NASDAQ: DRUG) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 2, 2026, Bright Minds announced that the FDA had notified the Company that it...
Back to Newsroom